会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Ether muscarinic antagonists
    • 醚类毒蕈碱拮抗剂
    • US5977138A
    • 1999-11-02
    • US910616
    • 1997-08-13
    • Yuguang WangWei K. ChangSundeep DugarSamuel Chackalamannil
    • Yuguang WangWei K. ChangSundeep DugarSamuel Chackalamannil
    • A61K45/06C07D211/46C07D211/96C07D405/12C07D405/14C07D409/14A61K31/445C07D401/04
    • C07D405/12A61K45/06C07D211/46C07D211/96C07D405/14C07D409/14
    • 1,4 Di-substituted piperidine muscarinic antagonists of formula I ##STR1## or an isomer, pharmaceutically acceptable salt, ester or solvate thereof, whereinX is a bond, --O--, --S--, --SO--, --SO.sub.2 --, --CO--, --C(OR.sup.7).sub.2 --, --CH.sub.2 --O--, --O-- CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --, --CH(C.sub.1 -C.sub.6 alkyl)-, --C(C.sub.1 -C.sub.6 alkyl).sub.2 --, --CONR.sup.17 --, --NR.sup.17 CO--, --O--C(O)NR.sup.17 --, --NR.sup.17 C(O)--O--, --SO.sub.2 NR.sup.17 -- or --NR.sup.17 SO.sub.2 --;R is cycloalkyl, optionally substituted phenyl or optionally substituted pyridyl;R.sup.2 is H, alkyl, optionally substituted cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted piperidinyl; and the remaining variables are as defined in the specification, are disclosed. Compounds of formula I are useful for treating cognitive disorders such as Alzheimer's disease. Also disclosed are pharmaceutical compositions, methods of preparation and combinations of compounds of formula I with ACh'ase inhibitors.
    • 1,4-二取代的式I的哌啶毒蕈碱拮抗剂或其异构体,药学上可接受的盐,酯或溶剂化物,其中X是键,-O - , - S - , - SO - , - SO 2 - , - ,-C(OR 7)2 - , - CH 2 -O - , - CH 2 - , - CH = CH - , - CH 2 - , - CH(C 1 -C 6烷基) - , - CONR 17 - , - NR 17 CO - , - OC(O)NR 17 - , - NR 17 C(O)-O-,-SO 2 NR 17 - 或-NR 17 SO 2 - R是环烷基,任选取代的苯基或任选取代的吡啶基; R2是H,烷基,任选取代的环烷基,环烯基,叔丁氧羰基或任选取代的哌啶基; 并且其余变量如说明书中所定义。 式I化合物可用于治疗认知障碍如阿尔茨海默病。 还公开了药物组合物,制备方法和式I化合物与ACh酶抑制剂的组合。
    • 10. 再颁专利
    • Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
    • 用作降胆固醇药的羟基取代的氮杂环丁酮化合物
    • USRE42461E1
    • 2011-06-14
    • US12797341
    • 1994-09-14
    • Stuart B. RosenblumSundeep DugarDuane A. BurnettJohn W. CladerBrian A. McKittrick
    • Stuart B. RosenblumSundeep DugarDuane A. BurnettJohn W. CladerBrian A. McKittrick
    • C07D205/08A61P9/10A61P3/06A61K31/395
    • C07D205/08A61K9/2018A61K9/4858A61K31/21A61K31/35A61K31/395A61K31/40A61K45/06Y02P20/55Y10S514/824A61K2300/00
    • Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
    • 羟基取代的氮杂环丁酮低胆固醇血药剂或其药学上可接受的盐,其中:Ar 1和Ar 2是芳基或R 4取代的芳基; Ar 3是芳基或者R 5取代的芳基; X,Y和Z是-CH 2 - , - CH(低级烷基) - 或-C(二卤代烷基) - 。 R和R 2为-OR 6,-O(CO)R 6,-O(CO)OR 9或-O(CO)NR 6 R 7; R1和R3是H或低级烷基; q为0或1; r为0或1; m,n和p为0-4; 条件是q和r中的至少一个为1,m,n,p,q和r的和为1-6; 并且条件是当p为O且r为1时,m,q和n的和为1-5; R4选自低级烷基,R5,-CF3,-CN,-NO2,卤素R5选自-OR6,-O(CO)R6,-O(CO)OR9,-O(CH2)1-5OR6, - O(CO)NR6R7,-NR6R7,-NR6(CO)R7,-NR6(CO)OR9,-NR6(CO)NR7R8,-NR6SO2R9,-COOR6,-CONR6R7,-COR6,-SO2NR6R7,S(O) -2R9,-O(CH2)1-10-COOR6,-O(CH2)1-10CON6R7, - (低级亚烷基)COOR6和-CH = CH-COOR6; R6,R7和R8是H,低级烷基或芳基取代的Ic R9是低级烷基,芳基或芳基取代的低级烷基; 以及通过单独或与胆固醇生物合成抑制剂组合含有它们的药物组合物来施用所述化合物来降低血清胆固醇的方法; 和一个准备它们的过程。